Finance Home - My Yahoo - Yahoo! - Help

Wednesday, February 10, 2010, 10:48AM ET - U.S. Markets close in 5 hours and 12 minutes. Dow  0.63% Nasdaq  0.69%

Amylin Pharmaceuticals, Inc. (AMLN)

At 10:33AM ET: 17.24   0.19 (1.09%)

MORE ON AMLN

Quotes Summary Real-Time Options Historical Prices Charts Interactive Basic Chart Basic Tech. Analysis News & Info Headlines Financial Blogs Company Events Message Board Company Profile Key Statistics SEC Filings Competitors Industry Components Analyst Coverage Analyst Opinion Analyst Estimates Research Reports Star Analysts Ownership Major Holders Insider Transactions Insider Roster Financials Income Statement Balance Sheet Cash Flow

Profile Get Profile for:
Amylin Pharmaceuticals, Inc. 9360 Towne Centre Drive Suite 110 San Diego, CA 92121 United States - Map Phone: 858-552-2200 Fax: 858-552-2212 Web Site: http://www.amylin.com DETAILS   Index Membership: N/A Sector: Healthcare Industry: Biotechnology Full Time Employees: N/A BUSINESS SUMMARY   Amylin Pharmaceuticals, Inc., a biopharmaceutical company, focuses on improving the lives of people with diabetes, obesity, and other diseases through the discovery, development, and commercialization of innovative medicines. The company has developed and gained approval for two medicines for diabetes, SYMLIN (pramlintide acetate) injection and BYETTA (exenatide) injection. The company also has research and development (R&D) programs in the therapeutic areas of diabetes and obesity. Its R&D programs for diabetes include exenatide once weekly, exenatide once weekly pen, exenatide suspension formulation, exenatide nasal, and the exenatide transdermal patch. The company’s R&D programs for obesity comprise pramlintide/metreleptin combination therapy and davalintide. Amylin Pharmaceuticals markets its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers, and other third-party payers primarily in the United States. It partners with Eli Lilly and Company for the development of exenatide; Alkermes, Inc. for the development of potential long-acting formulations of exenatide; and Biocon Limited to develop, commercialize, and manufacture a novel peptide therapeutic for the treatment of diabetes. Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California. Key Statistics COMPANY WEBSITES   Home Page Search Yahoo! for: More on Amylin Pharmaceuticals, Inc.		CORPORATE GOVERNANCE   Amylin Pharmaceuticals, Inc.'s Corporate Governance Quotient (CGQ®) as of 1-Feb-10 is better than 92.6% of Russell 3000 companies and 94% of Pharmaceuticals, Biotechnology & Life Sciences companies. Brought to you by Institutional Shareholder Services. View Financials KEY EXECUTIVES     Pay Exercised Mr. Dan Bradbury , 48 Chief Exec. Officer, Pres, Director and Member of Fin. Committee $ 655.00K $ 0 Mr. Mark G. Foletta CPA, 49 Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin. $ 409.00K $ 0 Dr. Orville G. Kolterman M.D., 62 Sr. VP R&D $ 432.00K $ 495.00K Ms. Marcea Bland Lloyd , 61 Sr. VP of Legal & Corp. Affairs and Gen. Counsel $ 470.00K $ 0 Mr. Roger Marchetti , 51 Sr. VP of HR & Information Management $ 356.00K $ 0 Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year. View Insiders
Add to Portfolio     Set Alert     Email to a Friend Get Profile for Another Symbol: Symbol Lookup • Annual Reports • Sector Analysis